Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/137113
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms |
Author: | Neill, E. Rossell, S.L. Yolland, C. Meyer, D. Galletly, C. Harris, A. Siskind, D. Berk, M. Bozaoglu, K. Dark, F. Dean, O.M. Francis, P.S. Liu, D. Phillipou, A. Sarris, J. Castle, D.J. |
Citation: | Schizophrenia Bulletin, 2022; 48(6):1263-1272 |
Publisher: | Oxford University Press |
Issue Date: | 2022 |
ISSN: | 0586-7614 1745-1701 |
Statement of Responsibility: | Erica Neill, Susan L. Rossell, Caitlin Yolland, Denny Meyer, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia M. Dean, Paul S. Francis, Dennis Liu, Andrea Phillipou, Jerome Sarris, and David J. Castle |
Abstract: | Background and hypothesis Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant proportion of individuals on clozapine continue to experience disabling symptoms, despite being treated with an adequate dose. There is a need for adjunct treatments to augment clozapine, notably for negative and cognitive symptoms. One such potential agent is the glutathione precursor N-acetylcysteine (NAC). Study design A randomized double-blind, multi-center, placebo-controlled trial for clozapine patients with enduring psychotic symptoms (n = 84) was undertaken to investigate the efficacy of adjunctive NAC (2 g daily) for negative symptoms, cognition and quality of life (QoL). Efficacy was assessed at 8, 24, and 52 weeks. Study results NAC did not significantly improve negative symptoms (P = .62), overall cognition (P = .71) or quality of life (Manchester quality of life: P = .11; Assessment of quality of life: P = .57) at any time point over a 1-year period of treatment. There were no differences in reported side effects between the groups (P = .26). Conclusions NAC did not significantly improve schizophrenia symptoms, cognition, or quality of life in treatment-resistant patients taking clozapine. This trial was registered with "Australian and New Zealand Clinical Trials" on the 30 May, 2016 (Registration Number: ACTRN12615001273572). |
Keywords: | mental illness; quality of life; cognition; depression; mental disorders; psychiatry; neuroscience |
Rights: | © The Author(s) 2022 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
DOI: | 10.1093/schbul/sbac065 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/GNT1098442 |
Published version: | http://dx.doi.org/10.1093/schbul/sbac065 |
Appears in Collections: | Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_137113.pdf | Published version | 1.63 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.